Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss
Background: Female pattern hair loss (FPHL) has a negative psychological and social impact. Lacks of consensus for its treatment as well as inconsistent response to treatment modalities are considered major challenges for physicians. Objectives: To assess the safety and efficacy of oral finasteride...
Saved in:
Main Authors: | Eman Hamed El Morsy, Asmaa Saad Abd Toto, Eman Mohamed Hassan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
Series: | Clinical Dermatology Review |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/cdr.cdr_87_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment
by: Naglaa Mohamed El Sayed, et al.
Published: (2025-01-01) -
Low-dose oral minoxidil in a case of short anagen syndrome
by: Divija Sharma, et al.
Published: (2025-12-01) -
Risk of poor glycemic control in tamsulosin versus finasteride users with type 2 diabetes mellitus
by: Minh-Ha Nguyen, et al.
Published: (2025-02-01) -
Assessment of Cardiovascular Risk Factors in Women Having Female Pattern Hair Loss
by: Damini Verma, et al.
Published: (2024-01-01) -
Effectiveness of autologous growth factor concentrates combined with topical minoxidil in patients of androgenic alopecia
by: Lavanya Maripati, et al.
Published: (2025-01-01)